Login to Your Account

Siding unanimously with new bid

Would shingle: FDA panel says yes to GSK's vaccine, Zostavax roof springs leak

By Randy Osborne
Staff Writer

Thursday, September 14, 2017

Shingrix (varicella zoster vaccine [recombinant], adjuvanted) from Glaxosmithkline plc (GSK) sailed through a hearing by the FDA's Vaccines and Related Biological Products Committee, with panelists voting 11-0 in favor of the product's efficacy and safety in people 50 years of age and beyond.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription